- Home
- ELBM vs QNCX Comparison
ELBM vs QNCX Comparison
Compare ELBM & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- QNCX
- Stock Information
- Founded
- ELBM 2011
- QNCX 2012
- Country
- ELBM Canada
- QNCX United States
- Employees
- ELBM N/A
- QNCX N/A
- Industry
- ELBM Industrial Machinery/Components
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELBM Miscellaneous
- QNCX Health Care
- Exchange
- ELBM Nasdaq
- QNCX Nasdaq
- Market Cap
- ELBM 29.6M
- QNCX 34.4M
- IPO Year
- ELBM N/A
- QNCX 2019
- Fundamental
- Price
- ELBM $0.50
- QNCX $2.08
- Analyst Decision
- ELBM Strong Buy
- QNCX Strong Buy
- Analyst Count
- ELBM 1
- QNCX 3
- Target Price
- ELBM $1.40
- QNCX $9.67
- AVG Volume (30 Days)
- ELBM 55.1K
- QNCX 1.1M
- Earning Date
- ELBM 11-15-2024
- QNCX 11-13-2024
- Dividend Yield
- ELBM N/A
- QNCX N/A
- EPS Growth
- ELBM N/A
- QNCX N/A
- EPS
- ELBM N/A
- QNCX N/A
- Revenue
- ELBM N/A
- QNCX N/A
- Revenue This Year
- ELBM N/A
- QNCX N/A
- Revenue Next Year
- ELBM $1,630.56
- QNCX N/A
- P/E Ratio
- ELBM N/A
- QNCX N/A
- Revenue Growth
- ELBM N/A
- QNCX N/A
- 52 Week Low
- ELBM $0.26
- QNCX $0.51
- 52 Week High
- ELBM $0.75
- QNCX $2.14
- Technical
- Relative Strength Index (RSI)
- ELBM 41.64
- QNCX 73.91
- Support Level
- ELBM $0.46
- QNCX $1.56
- Resistance Level
- ELBM $0.58
- QNCX $2.14
- Average True Range (ATR)
- ELBM 0.04
- QNCX 0.21
- MACD
- ELBM -0.00
- QNCX 0.02
- Stochastic Oscillator
- ELBM 35.04
- QNCX 91.89
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.